항비만약 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 작용기서별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

The global anti-obesity medication market size was valued at USD 19.5 billion in 2025 and is projected to grow from USD 25.7 billion in 2026 to USD 176.4 billion by 2033, growing at a CAGR of 31.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.0% in 2025. Increasing awareness of the health consequences of being overweight fuels market growth. In addition, the rising adoption of highly effective GLP-1 receptor agonists and next-generation weight loss therapies is significantly accelerating market expansion.

Accelerated development of anti-obesity drugs, supported by significant R&D investments, is expected to drive market growth. With advancements in drug development technologies, the market is poised for further growth, addressing the pressing need to combat overweight-related health challenges. In March 2025, the World Obesity Federation published the World Obesity Atlas, which projects that the number of obese adults will grow by more than 115% from 2010 to 2030, rising from 524 million to around 1.13 billion. The report states that two-thirds of countries lack most key national obesity policies, and only 7% have health systems adequately prepared to address obesity.

Furthermore, overweight and obesity are associated with approximately 1.6 million premature deaths annually from conditions including diabetes, cancer, heart disease, and stroke. The growing burden of obesity and inadequate healthcare preparedness is expected to accelerate demand for pharmacological interventions, thereby supporting market expansion. Moreover, the projected increase in obesity prevalence directly correlates with market growth, creating opportunities for pharmaceutical companies, healthcare providers, and other stakeholders. As healthcare costs associated with obesity continue to escalate, there is a growing imperative for innovative solutions and interventions to curb this epidemic and ensure sustainable healthcare cost containment.

Market players are actively investing in R&D to develop innovative medicines for weight management. For instance, in October 2025, Eli Lilly reported successful topline results from the Phase III trial, in which oral GLP-1 receptor agonist orforglipron achieved significant weight reduction and improvements in cardiometabolic risk factors in adults with obesity or overweight. These advancements are expected to intensify competition, broaden therapeutic options, and accelerate market growth.

The introduction of new medications such as CagriSema, Oral Sema Obesity, GELA, INV-202, and orforglipron is propelling the market growth. Investing in this sector enables companies to seize opportunities arising from evolving demands and gain a competitive edge. Leading the development and commercialization of innovative medications positions companies as frontrunners, consolidating their market presence.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Mechanism of Action
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Mechanism of Action outlook
  • 2.2.3. Distribution Channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Anti-Obesity Medication Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Prevalence of Obesity-Related Conditions
    • 3.2.1.2. Government Regulations and Guidelines
    • 3.2.1.3. Increase in technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Side Effects and Adverse Reactions
    • 3.2.2.2. High cost of anti-obesity drugs
• 3.3. Anti-Obesity Medication Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Anti-Obesity Medication Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Anti-Obesity Medication Market by Product Outlook
• 4.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Approved
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.1. Bupropion-naltrexone (Contrave)
      • 4.4.1.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.2. Liraglutide (Saxenda)
      • 4.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.3. Orlistat
      • 4.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3.2. Xenical
        • 4.4.1.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3.3. Alli
        • 4.4.1.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.4. Phentermine-topiramate (Qsymia)
      • 4.4.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.5. Semaglutide (Wegovy)
      • 4.4.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.6. Setmelanotide (Imcivree)
      • 4.4.1.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.1.7. Tirzepatide (Zepbound)
      • 4.4.1.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Off Label
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.1.1. Semaglutide (Ozempic)
        • 4.4.2.1.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.1.2. Liraglutide (Victoza)
        • 4.4.2.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.1.3. Dulaglutide (Trulicity)
        • 4.4.2.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.1.4. Topiramate (Dulaglutide (Trulicity))
        • 4.4.2.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.1.5. Other
        • 4.4.2.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Anti-Obesity Medication Market: Mechanism of Action Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Anti-Obesity Medication Market Movement Analysis
• 5.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Mechanism of Action, 2021 to 2033 (USD Million)
• 5.4. Peripherally Acting Drugs
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Centrally Acting Drugs
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Anti-Obesity Medication Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Anti-Obesity Medication Market Movement Analysis
• 6.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 6.4. Retail Pharmacies
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Hospital Pharmacies
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Anti-Obesity Medication Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Novo Nordisk A/S
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. GSK plc
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Novartis AG
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. VIVUS LLC
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Currax Pharmaceuticals LLC
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Boehringer Ingelheim International GmbH
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Rhythm Pharmaceuticals, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Gelesis
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives